Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
indobufen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| indobufen | DRUG | Indobufen capsules 100 and 200mg |
| aspirin | DRUG | Acetylsalicylic acid capsules 300mg |
Inclusion Criteria: * Chronic or paroxysmal non rheumatic atrial fibrillation with cardioembolic risk factors: hypertension, ischemic cardiopathy, Congestive Heart Failure, diabetes mellitus Exclusion Criteria: * Clinically relevant organ disease * creatinine clearance \< 30 ml/min * gastric or d...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
Indobufen is an investigational small molecule being studied for the prevention of thromboembolic events in patients with nonrheumatic atrial fibrillation. It is in Phase 3 clinical development for this cardiovascular condition.
Indobufen is being developed by Pfizer, Inc. (NYSE: PFE). The drug is currently in Phase 3 clinical trials for the prevention of thromboembolic events in patients with atrial fibrillation.
Indobufen is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 trial for atrial fibrillation has been completed.
Indobufen was studied in a Phase 3 clinical trial with the identifier NCT00244426, titled "S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation." This randomized, double-blind, active-controlled trial enrolled 1,372 participants in Italy and has been completed.
Yes, indobufen is a small molecule drug. It is being investigated for use in atrial fibrillation, a cardiovascular condition, and is currently in Phase 3 clinical development.